IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Examiner: SOLOLA, Taofiq A.

NAZARE, et al.

Art Unit: 1625

Application No.: 10/728,339

Filed: 4 December 2003

Title: IMIDAZOLE DERIVATIVES AS FACTOR Xa

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(b). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filling of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.57(b), constitute an admission that any patent, publication or other information referred to its, or is considered to be, material to the patental-litty of this invention. Pursuant to 37 C.F.R. 1.97(b), the filling of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

	(b)	This	is Information Disclosure Statement is filed after the period set forth in 37 C.F.R.			
		1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113			
		or a	notice of allowance under §1.311, whichever occurs first.			
		(1)	The undersigned attorney certifies that each item of information contained in this			
			Information Disclosure Statement was cited in a communication from a foreign			
			patent office in a counterpart foreign application not more than three months prior			
			to the filing of this statement;			
		(2)	The undersigned attorney certifies that no item of information contained in this			
			Information Disclosure Statement was cited in a communication from a foreign			
			patent office in a counterpart foreign application or, to the knowledge of the			
			undersigned attorney after making reasonable inquiry, was known to any			
			individual designated in §1.56(c) more than three months prior to the filing of this			
			statement; or			
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in			
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is			
			authorized.			
			Respectfully submitted,			
Δor	il.	12	2007			
Dated						
Dated			Jiang Lin, Reg. No. 51,065 Attorney/Agent for Applicant			
sanofi-ave	entis U	S.LLC				

sanofi-aventis U.S. LLC U.S. Patent Operations Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3582 Telefax (908) 231-2626 sanofi-aventis Docket No. DEAV2002/0085 US NP

Please type a plus sign (+) inside th	his box →	✓
---------------------------------------	-----------	---

PTO/SB/08A (10:96) Approved for use through 10/3199, OMB 9651-0331 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known Application Number 10,728,339 INFORMATION DISCLOSURE Filing Date 12-04-2003 STATEMENT BY APPLICANT First Named Inventor NAZARÉ, et al Group Art Unit (use as many sheets as necessary) Examiner Name SOLOLA, Taofin A Sheet of 1 Attorney Docket Number DFAV2002/0085 - US - NP

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.1	Number	t Document Kind Code ² (4 known)	or Caled Document	Date of Publication of Cited Document MM-DD-YYYY	Pagea, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US2005-000		NAZARÉ, et al.	01-13-2205	
		US2005-000		NAZARÉ, et al.	01-13-2005	
		US2004-023	35824	NAZARÉ, et al.	11-25-2004	
		US2005-000	9829	NAZARÉ, et al.	01-13-2005	
	_	7,196,103		NAZARÉ, et al.	03-27-2007	
		US2005-004	13302	NAZARÉ, et al.	02-24-2005	
		6,906,084		NAZARÉ, et al.	06-14-2005	
		6,953,857		NAZARÉ, et al.	10-11-2005	
		7,087,865		NAZARÉ, et al.	08-27-2006	
		US2007-004	19573	BAUER, et al.	03-01-2007	
		11/469,513		URMANN, et al.	09-01-2006	
		US2004-020	14406	NAZARÉ, et al.	10-14-2004	
			\neg			
\neg			\neg			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials		$\overline{}$	Foreign Patent Do	Current Knd Code*		Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Pessages or Relevant Figures Appear	Te.
		Office ³	Number ⁴	(FAnower)	Applicant of Cited Document	MM-DD-YYYY		
\vdash	-	 		-11				⊢
	_							+
_	_	-		-				
	_	-						╁
	_							
	-			-H				⊢
								+

Examiner Signature		Date Considered			
"EXAMINER: Initial if reference considered, whether or not obtains in conference with MECD 600. Draw less the control of and in conference and and					

ce considered, whether or not obtain is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant.

Unique citation designation number, ²See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two latter Code (WIPO Sundard ST.3). 4 for Japanese patient document, be indication of the year of the region of the Emperor most procede the serial number of the patient document. 9 Kind of document by the appropriate symbols as indicated on the document under WIPO Sundard ST. 16 If possible. * Applicant is to place a check mark here if English language Translation is attached.